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Stephen Wan Leung1,2† and Tsair-Fwu Lee3*†Abstract
Purpose: To analyze of survival curve and toxicity outcomes for patients treated for nasopharyngeal carcinoma
(NPC) by intensity-modulated radiotherapy (IMRT) delivered by helical TomoTherapy (HT).
Materials and methods: Since May 2006, 72 patients with primary NPC were treated. In 67 cases PET-CT was used
to help delineate the gross tumor volume (GTV); in 4 of these cases distant metastases in bone, mediastinal lymph
nodes and unexpected small neck nodes were detected by high SUV uptake. 3, 22, 19, and 27 patients, respectively,
had AJCC stage I to IV disease. Patients received a median total dose of 72 Gy to the GTV, 64.8 Gy to the elective
PTV, and 54 Gy to the clinically negative neck region.
Results: At a median follow-up of 41 months (range 0.2 to 67 months), no patient has recurred locally. Two
patients with stage IIb disease, both of whom received chemotherapy, recurred regionally. Ten patients developed
distant metastases. One died from progressive disease with initial proved bony metastasis. Two patients with stage
IIb disease, both of whom received chemotherapy, experienced neck node recurrence. 5-year locoregional control
rate was 97%; freedom from distant metastases was 84.6% at 5 years. No evidence of disease was detected in 13
early stage (I/IIa/IIb) patients who did not receive chemotherapy. Acute grade 3 toxicity occurred in four patients
and grade 4 in two patients. Late toxicities were low, with no grade 3+ xerostomia, grade 2 xerostomia in two
patients (3%), and grade 3 hearing loss in two patients (3%).
Conclusions: HT resulted in excellent long-term disease control and survival in heterogeneous NPC patients.
Generally mild acute and late toxicity, with low rates of xerostomia, were obtained. Image-guided HT offers the
ability to deliver conformal, OAR-sparing dose distributions to a wide variety of NPC patients with good long-term
clinical outcomes.Introduction
In 2002 the United States Food and Drug Administration
(FDA) approved an innovative radiation therapy device
called Helical TomoTherapy® (HT; Accuray Incorporated,
Sunnyvale, CA). The 3-dimensional imaging provided by
megavoltage CT allows for accurate patient setup and
precise radiation delivery [1-3]. The helical delivery of
intensity-modulated radiotherapy (IMRT) allows excellent
conformality and homogeneity of the radiation dose dis-
tribution [4-9]. The advantage of its unique approach to
radiation delivery is especially clear for complicated dose* Correspondence: tflee@kuas.edu.tw
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reproduction in any medium, provided the ordistributions involving multiple planning target volumes
(PTVs) and organs at risk (OAR), such as those often
required for adequate and safe treatment of head and neck
cancer [5,9].
Considerable research with the HT system has focused
on dosimetry of head and neck plans relative to other
radiation therapy platforms. In general these studies
indicate that HT plans are superior to step-and-shoot
(SaS) IMRT plans in terms of target coverage and OAR
sparing, or superior to or comparable to arcing IMRT
plans, depending on the parameter under consideration.
For example, Lee et al. [9] showed that HT plans were
more conformal and homogeneous than SaS-IMRT
plans, and that the dose to most of the OARs was lower
in HT plans (in patients without skull base infiltration
HT did not lower the dose to the optic chiasm). Similar
outcomes have been obtained in several other studiesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics (n = 72)
Variables Number (%)










II a/b 7/16 (total 32%)
III 19 (26%)
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non-arcing IMRT when compared with HT plans;
Wiezorek et al. obtained generally superior OAR sparing
with arcing IMRT plans in their study of 10 head and
neck cancer patients, but concluded the overall plan
quality was best for HT.
The first clinical outcomes for HT treatment of head
and neck cancer have recently been published. Kodaira
et al. [13] used HT to treat 20 pts with NPC, some
node-positive and with metastases, most of whom
underwent chemotherapy. The progression-free and
overall survival rates at 10 months were 79.7% and 95%,
respectively. Parotid function assessed by quantitative
salivary scintigraphy showed a drop in maximal excre-
tion ratio at 3 months which returned to near baseline
by one year; at 3 months 61.1% of patients had Grade 2
and 38.9% had Grade 1 xerostomia, but by 9 months,
Grade 2 xerostomia was observed in 26.7% of patients,
Grade 1 in 66.7%, and Grade 0 in the rest. Most recently
Chen et al. [14] studied patients treated for nasopha-
ryngeal cancer (NPC) using HT or IMRT delivered via
segmental multileaf collimator. They replicated the
dosimetric superiority of HT, showing significant reduc-
tions in dose to parotids, temporal lobes, and ipsilateral
ear structures. Overall survival and disease control for
the two groups was nearly identical. Although RTOG-
graded scoring of late xerostomia was not significantly
different (13% for IMRT vs 7% for HT), 38% of IMRT
patients (7 of 16 patients) reported “too little” or “no”
saliva using the University of Washington quality of life
survey (UW-QOL), while 7% (1 of 14 patients) of HT
patients reported too little saliva. The authors concluded
that the dosimetric differences between HT and SaS-
IMRT did, indeed, result in improved clinical outcomes.
Despite these instances, published clinical data on HT
for NPC is sparse. Here we present long-term (5 year)
clinical outcomes of HT for 72 patients with nasopha-
ryngeal cancer.Stage IIa 3 patients
Stage IIb 7 patients





AJCC, American Joint of Cancer Committee in 2007.Materials and methods
Patients
Since May 2006, 72 patients (59 men and 13 women)
with primary NPC were treated with curative RT by HT
in the Department of Radiation Oncology, Kaohsiung
Yuan’s General Hospital. Patient characteristics are indi-
cated in Table 1. The median age was 46.5 years (range
23 to 80 years). The distribution of clinical stages
according to the American Joint of Cancer Committee
(AJCC) staging system published in 1997 was 3 patients
(4%) at Stage I, 23 (32%) at Stage II, 19 (26%) at Stage
III, and 27 patients (37.5%) at Stage IV. Forty-five
patients (62.5%) received concomitant chemotherapy,
and 27 patients (37.5%) did not. This study was approvedby the Medical Ethics Committee of the Kaohsiung
Yuan’s General Hospital (YUAN-IRB20120328B). Writ-
ten informed consent was obtained from the patient
for publication of this report and any accompanying
images.
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All patients were immobilized in a tailor-made thermo-
plastic cast from head to shoulders, and 3 mm-thickness
CT (12 patients) and/or PET/CT (67 patients; Siemens
Biograph LSO PET/CT) scan slices of the head and neck
were obtained to be used for localization of targets and
organs at risk (OARs). CT or PET/CT image sets were
then transferred to and fused in the Pinnacle3 planning
system (Phillips Healthcare, The Netherlands) for con-
touring. Contours were transferred to HT for IMRT in-
verse planning. In four of the patients simulated with
PET/CT, distant metastases in bone, mediastinal lymph
nodes and unexpected small neck nodes were detected
by high SUV uptake.
The gross tumour volume (GTV), including the
macroscopic primary cancer and nodes greater than
1 cm in diameter or nodes with necrotic centres, was
used for all plans. RT was delivered using a sequential
IMRT technique and three cone-down target volumes
were defined for each patient. According to the RTOG
0225 and previous studies [15-18], for a typical case by
using the prescribed dose equals to 72 Gy, the clinical
target volume (CTV) for the delivery of absorbed dose
of 72 Gy (CTV72 = GTV + 5 mm margin) is defined
using an isotropic margin of 5 mm around the GTV.
The clinical target volume for 64.8 Gy delivery (CTV64.8)
equals to the CTV72 + 5 mm margin plus areas at risk
for microscopic involvement, including the entire
nasopharynx, retropharyngeal nodal regions, skull base,
clivus, pterygoid fossae, parapharyngeal space, sphenoid
sinus (in T3-T4 disease, the entire sphenoid sinus), the
posterior third of the nasal cavity/maxillary sinuses that
includes the pterygopalatine fossae, and levels I through
V nodal regions. The cavernous sinus should be included
in high-risk patients (T3, T4, bulky disease involving the
roof of the nasopharynx). The clinical target volume for
54 Gy (CTV54) includes the clinically negative low neck
regions. Safety margins between the CTV and planning
target volume (PTV) of 5 mm were used for CTV72 and
CTV64.8 to account for patient setup error and motion
uncertainties, but in areas in which the GTV or the CTV
was adjacent to critical normal structures (i.e., the brain-
stem) the margin was reduced to 1 mm; no safety margin
was used for the generation of planning target volume-
54Gy (PTV54). In our study cohort, the median (and
modal) prescribed dose was 72 Gy to the PTV (39.6 Gy to
75.6 Gy) (PTV72), 64.8 Gy to the elective PTV(PTV64.8),
and 54 Gy to the clinically negative neck region (PTV54)
with a daily fraction size of 1.8 Gy in terms of three cone-
down treatment schemes. Typically for the prescribed
dose equal to 72 Gy, the prescription dose was set to (a)
28 fractions containing all three PTVs, (b) eight fractions
containing PTV72 and PTV64.8, and (c) four fractions
treated with PTV72 alone. OARs included seven serial-type organs (serial OARs; brainstem, spinal cord, lenses,
eyes, optic nerves, chiasm, and mandible) and three
parallel-type organs (parallel OARs; parotids, subman-
dibular glands, and oral cavity). Maximum doses to OARs
were optimized on an individual basis without compro-
mising the PTV coverage, with at least 95% of the PTV
receiving the minimum prescribed dose. Fifteen patients
(21%) also received intracavitary brachytherapy delivered
to the GTV, 3–6 Gy in 1–2 fractions delivered twice per
week, the dose prescribed to 2 cm off the source axis.
Treatment delivery
Treatment was delivered in five fractions per week. Daily
patient setup began with laser-based positioning fol-
lowed by MVCT scanning using the coarse setting.
Offsets were used to correct patient positioning. IMRT
was delivered with a 2.5 cm field width, a pitch of 0.3,
and a modulation factor of 2.5. These settings have been
shown in prior work to produce plans that are superior
to 7-field step-and-shoot IMRT plans [9]. Repeat CT
simulation occurred 2 to 3 times during treatment to
allow cone-down boosting and plan adaptation to meet
dosimetric goals for PTVs and maintain dose constraints
to OARs.
Concurrent chemotherapy was administered in 45
(62.5%) patients. For most patients this consisted of
cisplatin and fluorouracil; some patients were treated
with combinations that included oxaliplatin, tegafur-uracil
(Ufur), hydroxyurea, carboplatin, or erbitux.
Patients follow-up
Patients were evaluated for disease control, survival, and
toxicity according to RTOC toxicity criteria at 2-month
intervals for the first 2 years, at 3- to 6-month intervals
between the third and fifth years, and at 1-year intervals
thereafter. Follow-up examination of the primary tumor
was assessed by fiberoptic endoscopy at every visit. CT
scan, bone scans, chest radiography, and liver sonog-




Highly conformal, homogeneous treatment plans were
generated for HT [9]. Table 2 shows that dose constraints
for organs at risk were generally maintained. In particular,
both ipsilateral and contralateral parotid glands were held
below the 26 Gy dose constraints. Doses to OARS were
always less than doses recommended under RTOG proto-
col 0615.
Disease control
At a median follow-up of 41 months, no patient has
recurred locally. Two patients with stage IIb disease,
Table 2 The mean or maximum doses to organs at risk
(OARs)
OARs Mean value ± SD (Gy) Range (Gy)
Serial Maximum dose
Brain stem 50.53 ± 1.78 46.40–52.75
Spinal cord 39.95 ± 1.95 35.86–42.90
Ipsi-lateral lens 3.78 ± 0.78 2.63-4.70
Contra-lateral lens 3.58 ± 0.70 2.60-4.60
Ipsi-lateral eye 11.19 ± 3.10 6.76-17.69
Contra-lateral eye 10.38 ± 2.51 6.53-15.86
Mandible 63.64 ± 1.72 60.17-65.44
Chiasm 38.20 ± 4.67 15.20-46.50
Parallel Mean dose
Ipsi-lateral parotid gland 22.07 ± 1.66 19.18-24.99
Contra-lateral parotid gland 20.46 ± 2.27 15.48-24.56
Submandibular glands 31.92 ± 2.65 27.85–37.09
Oral cavity 32.49 ±6.09 22.19–41.06
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node recurrence. Kaplan-Meier (KM) analysis resulted in
a 5-year estimate of locoregional control of 97% (see
Figure 1). One of these patients was treated surgically
and is currently without evidence of disease; the other
was lost to follow-up. Ten patients had been proved for
distant metastasis; KM freedom from distant metastases
was 84.6% at 5 years (Figure 1). Metastases occurred to
bone, lung, and liver, and 5 patients presented with
multiple metastatic sites. One patient died for diseaseFigure 1 Locoregional progression-free survival (yellow) and
freedom from distant metastases (blue). The 5-year locoregional
control estimate was 97% (95% CI = 88.7% – 99.2%). KM freedom
from distant metastases was 84.6% at 5 years (95% CI = 72.9% – 91.5%).
Below the figure is shown the patients at risk at different time points;
LR indicates locoregional DM indicates distant metastases.out of control with initial proved bony metastasis. No
evidence of disease was detected in 13 early stage (I/IIa/
IIb) patients who did not receive chemotherapy. Seven
patients have died of cancer; overall survival at
40 months mean follow-up was 90%.
Toxicity
Most patients experienced no serious acute toxicity
(Table 3). RTOG Grade 2 acute mucositis was observed
in 6 patients (8%), Grade 3 in 3 patients (4%), and Grade
4 in 1 patient (1%). Grade 2 dermatitis occurred in 8
patients (11%), Grade 3 in no patients, and Grade 4 in 1
patient (1%). All patients with Grade 3 and 4 acute
toxicities were also treated concurrently with chemo-
therapy. Late toxicity was generally very mild, with
Grade 2 xerostomia in 2 patients (3%) and no Grade 3+
xerostomia. Grade 2 dysphagia occurred in 1 patient,
with no Grade 3+ dysphagia. Grade 3 hearing loss was
observed in 2 patients (3%) who also received concur-
rent chemotherapy.
Discussion
The dosimetric advantages of HT for head and neck
cancer have been reported in numerous publications,
but few studies report on clinical outcomes of HT. The
current study is among the largest, with the longest
follow-up, reported in the literature to date. Its results
demonstrate outstanding long-term disease control with
acceptable levels of toxicity for NPC treated by NPC.
By allowing safe dose escalation to high-risk regions
and simultaneous broad-field treatment of low-risk
regions, IMRT has, arguably, enhanced NPC treatment
efficacy and safety [17]. Lee et al. reported results from a
multi-institutional trial of 68 patients with NPC treated
with IMRT with or without chemotherapy [19]. Most
patients received 70 Gy to the GTV and 59.4 Gy to sub-
clinical regions. At a median follow-up of 2.6 years the
2-year estimate of local control was 92.6%, progression-
free survival was 72.7%, and overall survival 80.2%.
Grade 4 acute toxicities were observed in 11.8% andTable 3 Acute and late toxicity (RTOG grading criteria)
Grade
Acute toxicity (N/%) 0 1 2 3 4
Mucositis 42 (58) 20 (28) 6 (8) 3 (4)* 1 (1)*
Dermatitis 13 (18) 50 (69) 8 (11) 0 (0) 1 (1)**
Late Toxicity (N/%) 0 1 2 3 4
Xerostomia 21 (29) 49 (68) 2 (3) 0 (0) 0 (0)
Dysphagia 65 (90) 6 (8) 1 (1) 0 (0) 0 (0)
Hearing loss 35 (49) 34 (47) 1 (1) 2 (3) 0 (0)
Other 72 (100) 0 (0) 0 (0) 0 (0) 0 (0)
*Patients received cisplatin, fluorouracil, Ufur.
**Patient received oxaliplatin.
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1 year was present in 13.5%. Wolden et al. [20] treated
74 patients to 70 Gy with GTV boosting; most patients
received concurrent and adjuvant platinum-based
chemotherapy. At a median follow-up of 35 months
the 3-year actuarial local control estimate was 91%;
progression-free survival and overall survival was 67%
and 83%, respectively. Long-term Grade 2 xerostomia
occurred in 32% of patients (no Grade 3). Similar rates
of long-term local disease control and overall survival,
with Grade 2–3 xerostomia related to parotid dose [21],
were reported by others using IMRT [21,22].
More recently reports of HT for locally advanced NPC
have begun to appear. Kodaira et al. [13] treated 20
patients to 70 Gy to the tumor PTV and 54 Gy to the
nodal PTV in 35 fractions. At a median follow-up of
10.3 months, 2 patients developed recurrent disease, in
the liver in one patient and in a lymph node included in
the tumor PTV for another. Progression-free and overall
survival was 79.7% and 95%, respectively. Shueng et al.
[23] followed 28 patients to a median of 33 months after
neoadjuvant chemotherapy followed by concurrent
chemoradiation including HT to 70 Gy to the tumor
and positive nodes. The 3-year local, regional, loco-
regional control and distant metastasis rate were 92.4%,
95.7%, 88.4%, and 78.0%, respectively, and overall
survival was 83.5%. Toxicities generally occurred at a low
rate, and late Grade 2 xerostomia was observed in 14% of
patients (no Grade 3+). Ren et al. [24] treated 73 patients,
24 with radiation only, with 70–74 Gy in 33 fractions to
tumor PTV (primary tumor and positive lymph nodes),
with 60–62.7 Gy a high-risk and 52–56 Gy to a low-risk
PTV. At a median follow-up of 14.8 months the 1-year
relapse-free survival, distant metastasis-free survival and
overall survival were 95.6%, 97.2% and 94.8%, respectively.
By one year post-radiotherapy no patient reported Grade
2+ xerostomia. In this context the current results compare
favorably; at a median of 41 months follow-up, with
several patients followed beyond 4 and 5 years, no patient
recurred locally. Two regional recurrences and 10 distant
metastases were obtained, and to date seven deaths due to
cancer has occurred. Mean parotid doses were very low—
22.07 Gy and 20.46 Gy to the ipsilateral and contralateral
glands, respectively—and late Grade 2+ xerostomia
occurred in only 3% of patients. We conclude that the
ability of HT to effectively target multiple regions of differ-
ing disease burden within the head and neck field while
maximally sparing OARs, combined with daily MVCT-
guided patient setup accuracy and a rational regimen of
systemic treatment, results in robust disease control with
limited toxicity.
Although local control and survival have been enhanced
by the introduction of IMRT into NPC treatment, the pat-
tern of recurrence continues to show a relatively high rateof distant metastases [17,20,21,23], suggesting the con-
tinuing need for more effective systemic therapies. In
addition, it cannot be determined whether the generally
superior dose-sculpting capability of HT relative to more
conventional IMRT leads to improved disease control and
toxicity outcomes. A recent paper by Chen et al. [14]
reported on a comparison of 16 patients treated with
IMRT delivered by sequential multileaf collimator and 14
with HT. Survival and disease control were identical
between groups; 2-year local control was 87% in both
groups, and overall survival did not differ significantly.
The rate of xerostomia at any point in the late setting did
not differ significantly between groups; at last follow-up,
however, 38% of IMRT patients reported “too little” or
“no” saliva, versus 7% of HT patients. Thus, recovery from
xerostomia occurred more readily in the HT group. In a
study by our group of quality-of-life between IMRT and
HT patients, substantial improvements in saliva and
oropharyngeal QOL variables were obtained with HT (in
preparation). Thus, although for many patients superior
HT treatment plans may have little effect on outcomes,
for a significant subset the ability to easily reduce dose to
parotids and other structures can be important for long-
term QOL.
Potential limitation for this study may exist. Xero-
stomia related symptoms were usually cited as the most
prevalent complications in NPC survivors post radio-
therapy and patient-reported xerostomia has been found
to significantly correlate with mean dose to the parotid
glands and the minor salivary glands. Assessment of
treatment-related toxicity by the well-validated health-
related quality of life questionnaire rather than RTOC
toxicity criteria would provide more informative data for
the comparison among different studies.
The outcomes of the present study require additional
long-term follow-up to assess the robustness of the
promising disease control and low toxicity observed to
date. In addition, the single-institution nature of the
current study suggests a need to expand the HT meth-
odology employed here to different patient populations
in different institutions. In the meantime we are encou-
raged by the relatively low toxicity and excellent disease
control with HT and, in selected patients, chemotherapy,
to carry on with this approach to treating patients with
locally advanced nasopharyngeal carcinoma.
Conclusions
Modern, advanced technology has brought the radiation
oncology of head and neck cancer to a new era. We can
generate better conformity and homogeneity than ever.
In our clinical practice, acute and late complications
after HT for NPC are definitely fewer and milder com-
pared with our conventional IMRT technique. Helical
TomoTherapy appears to have the advantages compared
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distribution, and quality of life, local control and survival
for our patients. Nevertheless, HT appears to have dosi-
metric advantages compared to IMRT which might trans-
late into a significant benefit for the patients in clinical
practice. To our knowledge, charged particles, such as
proton beam or carbon ion beam, may have the best
dosimetry for NPC plans. Comparison of the treatment
outcomes of TomoTherapy to that of charged particles
would be an interesting issue and warrants further
investigation.
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